



## BACKGROUND

- HIV pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention.
- The oral PrEP formulation of tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) is highly effective for HIV prevention, but its efficacy may limited by incomplete adherence.
- In addition, TDF-FTC may impact bone mineral density (BMD), raising safety concerns for longterm usage.
- In HPTN 083, long-acting cabotegravir (CAB-LA) was found to be superior to TDF-FTC for HIV prevention.
- However, the relative bone safety of these regimens is unknown.

## **METHODS**

- HPTN 083 is a randomized (1:1), double-blind, double-dummy, noninferiority trial comparing CA LA (600 mg, given intramuscularly every 8 weeks to daily oral TDF-FTC for the prevention of HIV infection in at-risk cisgender men who have sex with men (MSM) and in at-risk transgender women who have sex with men.
- A Bone Substudy was conducted at 19 sites
- BMD was measured at the lumbar spine (LS), femoral neck, and total hip by dual-energy x-ray absorptiometry (DXA) at baseline, 57 weeks, and 105 weeks.
- Scans were analyzed centrally (Tufts University, Medford, MA).
- Percentage BMD change at each anatomic site compared between the two randomized arms by two-sample, independent t-tests in those who received at least 10 ten bi-monthly injections ove 18 months from enrollment (i.e, as treated population). Models were adjusted for age and race given demographic differences in randomize groups.

# **BONE DENSITY CHANGES WITH CAB-LA OR TDF/FTC PrEP** 987 IN MSM AND TGW IN HPTN 083 **Todd T. Brown**<sup>1</sup>, Robert F Arao<sup>2</sup>, Nittaya Phanuphak<sup>3</sup>, Esper Kallas<sup>4</sup>, Tomitope Oyedele<sup>5</sup>, Richard Berman<sup>6</sup>, Philip A Sullivan<sup>1</sup>, Brett Hanscom<sup>2</sup>, Adeola Adeyeye<sup>7</sup>, James Rooney<sup>8</sup>, Alex Rinehart<sup>9</sup>, Marybeth McCauley<sup>10</sup>, Beatriz Grinsztejn<sup>11</sup>, Raphael J Landovitz<sup>12</sup>, HPTN 083 Study Team

Johns Hopkins University, Baltimore, MD, USA<sup>1</sup>, Fred Hutchinson Cancer Center, Seattle, WA, USA<sup>2</sup>, Thai Red Cross, Bangkok, TH<sup>3</sup>, University of Sao Paulo, Sao

be	In cisgender men a women initiating H was associated wit whereas TDF-FTC over 2 years. Espe with low BMD or of
B- s)	factors, CAB-LA Pr important strategy health.
en	

#### RESULTS

Table 1. Baseline	e Characteristics		Table 2. Bone Mineral Density Z-scores at Baseline			
	<b>TDF/FTC</b>	CAB-LA		TDF/FTC	CAB-LA	
Median (Q1, Q3) or	· % (N=122)	(N=132)	Mean Z-score (SD)	(N=122)	(N=132)	
Age (years)	29.0 (23.0, 41.0)	26.0 (22.0, 31.0)	Lumbar Spine	-0.44 (1.2)	-0.59 (1.4)	
Race			Femoral Neck	-0.23 (1.0)	-0.21 (1.1)	
ASIAN	15%	9%	Total Hip	-0.26 (1.0)	-0.28 (1.0)	
BLACK	25%	36%	Low BMD** %	14.8%	16.2%	
OTHER	13%	7%	*Z-score is number of standard deviations from the average BMD in age-, race-matched population **Z-score $\leq$ -2.0 at either lumbar spine, femoral neck, total hip			
WHITE	47%	48%	• At baseline, BMD was 0.2-0.6 SD lower than a age-, sex-,			
Transgender Women	Transgender Women8%11%			race-matched reference population (i.e Z-scores -0.2 to -0.6)		

Young population with most at the age of peak BMD • 8% were 50 years old or older

Overall support for the HIV Prevention Trials Network (HPTN) is provided by the National Institute of Allergy and Infectious Diseases (NIAID), Office of the Director (OD), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under Award Numbers UM1AI068619-15 (HPTN Leadership and Operations Center), UM1AI068617-15 (HPTN Statistical and Data Management Center), and UM1AI068613-15 (HPTN Laboratory Center).

and transgender IV PrEP, CAB-LA th BMD gain, led to BMD loss ecially for individuals ther fracture risk rEP may be an to preserve bone

• 15% had low BMD (Z-score  $\leq$  -2.0 at either lumbar spine, femoral neck, total hip)

Percent BMD Difference From Enrollment by Study Arm



• BMD decreased in the TDF-FTC arm by 0.5-1.0% BMD increased in CAB-LA arm 0.5-1.5% • After adjusting for age and race, BMD measures were significantly higher at follow-up visits among participants receiving CAB-LA compared to those receiving TDF/FTC (Z-score difference 0.09-0.20 at Week 105)

# CONCLUSIONS

 Among cisgender men MSM and transgender women, HIV PrEP with CAB-LA was associated with increases in BMD, whereas TDF-FTC led to decreases in BMD.

As observed in other PrEP studies, this population had lower BMD than the reference population (NHANES), with  $\sim 15\%$  having low BMD.

8% of the study population were 50 years or older Given the relationship between low BMD and subsequent fracture, persons at higher risk of fracture because of older age, lower BMD, or other osteoporosis risk factors, who are interested in PrEP may consider CAB-LA to maintain bone health.

Longer-term follow-up will be required to evaluate the clinical significance of these findings.